SCHEMBL5822283

SCHEMBL5822283

O=C(O)Cn1cc(/C=C2\C(=O)Nc3ccccc32)c2ccccc21

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 14/20 0.75
DHFR P00374 4/20 0.72
MEN1 O00255 12/20 0.68
POLB P06746 4/20 0.68
MAPT P10636 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
NPSR1 Q6W5P4 2/20 0.68
L3MBTL1 Q9Y468 2/20 0.65
NTRK1 P04629 1/20 0.64
MAP3K5 Q99683 1/20 0.64
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
APEX1 P27695 1/20 0.58
RECQL P46063 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
SYK P43405 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5822284 1.00 KMT2A (0.75) KMT2ADHFRMEN1POLBMAPT
SCHEMBL26434393 1.00 KMT2A (0.75) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5476100 0.89 DHFR (0.70) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5476102 0.89 DHFR (0.70) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5476058 0.87 KMT2A (0.77) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5476060 0.87 KMT2A (0.77) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5482789 0.85 KMT2A (0.66) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5482792 0.85 KMT2A (0.66) KMT2ADHFRMEN1POLBMAPT
SCHEMBL14448896 0.85 SIRT1 (0.71) KMT2ADHFRMEN1POLBMAPT
SCHEMBL5822237 0.83 KMT2A (0.66) KMT2ADHFRMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
WO-2006105796-A1 NOVEL INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 KMT2A 1891/4885DHFR 3147/4885MEN1 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.